BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24397291)

  • 1. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?
    Guenova E; Hoetzenecker W; Rozati S; Levesque MP; Dummer R; Cozzio A
    Expert Opin Investig Drugs; 2014 Apr; 23(4):457-67. PubMed ID: 24397291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
    Chung CG; Poligone B
    Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies for cutaneous T-cell lymphomas.
    Horwitz SM
    Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment.
    Geller S; Hollmann TJ; Horwitz SM; Myskowski PL; Pulitzer M
    Histopathology; 2020 Jan; 76(2):222-232. PubMed ID: 31355940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.
    Van-de-Velde V; Zhou Y
    J Cutan Med Surg; 2019; 23(3):319-327. PubMed ID: 30943788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
    Lansigan F; Foss FM
    Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
    Duvic M
    Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
    Chung CG; Poligone B
    Dermatol Clin; 2015 Oct; 33(4):787-805. PubMed ID: 26433850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
    Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
    Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies against cutaneous T-cell lymphomas.
    Alaibac M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1503-1510. PubMed ID: 28829215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for cutaneous T-cell lymphomas.
    Kaplan JB; Guitart J; Giles FJ
    Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop.
    Quintanilla-Martinez L; Jansen PM; Kinney MC; Swerdlow SH; Willemze R
    Am J Clin Pathol; 2013 Apr; 139(4):491-514. PubMed ID: 23525618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for the treatment of cutaneous T-cell lymphoma.
    Cheng M; Zain J; Rosen ST; Querfeld C
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):45-54. PubMed ID: 35235473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
    Pileri A; Delfino C; Grandi V; Pimpinelli N
    Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
    Xu S; Foss F
    Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma.
    Beljaards RC; Meijer CJ; Van der Putte SC; Hollema H; Geerts ML; Bezemer PD; Willemze R
    J Pathol; 1994 Jan; 172(1):53-60. PubMed ID: 7931828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.